Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV or Flu H5 Vaccines in Healthy Participants
NCT07516418Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of RSV vaccine in respiratory syncytial virus infection (RSV) and Influenza A H5N1 (H5N1) (12 arms), sponsored by Sanofi. Primary endpoints: Presence of any unsolicited systemic Adverse Events at Day 1, Presence of solicited injection site reactions and 12 more. Started Apr 2026; status: recruiting.
02
Drugs
RSV vaccine
03
Conditions
respiratory syncytial virus infection (RSV)Influenza A H5N1 (H5N1)
Beyond the preview
Go deeper on NCT07516418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516418.